Breaking World Pharma News

Ebola vaccine trials fast-tracked by international consortium

FRIDAY, 29 AUGUST 2014

GlaxoSmithKline

A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in west Africa.

NIH to launch human safety study of Ebola vaccine candidate

THURSDAY, 28 AUGUST 2014

Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The early-stage trial will begin initial human testing of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and will evaluate the experimental vaccine's safety and ability to generate an immune system response in healthy adults.

Fighting prostate cancer with a tomato-rich diet

THURSDAY, 28 AUGUST 2014

Men who eat over 10 portions a week of tomatoes have an 18 per cent lower risk of developing prostate cancer, new research suggests. With 35,000 new cases every year in the UK, and around 10,000 deaths, prostate cancer is the second most common cancer in men worldwide. Rates are higher in developed countries, which some experts believe is linked to a Westernised diet and lifestyle.

Aspirin cuts risk of clots, DVT by a third

WEDNESDAY, 27 AUGUST 2014

Low dose aspirin lowers the occurrence of new venous blood clots - and represents a reasonable treatment option for patients who are not candidates for long-term anticoagulant drugs, such as warfarin, according to a new study published in current issue of Circulation. The aspirin tablets manufactured by Taj Pharmaceuticals Limited., - Mumbai, India- www.tajpharma.com

Pfizer and Merck to collaborate on study evaluating novel anti-cancer combination regimen

TUESDAY, 26 AUGUST 2014

Pfizer

Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's crizotinib (XALKORI®) with Merck's investigational anti-PD-1 antibody pembrolizumab,

Roche and InterMune reach definitive merger agreement

MONDAY, 25 AUGUST 2014

Roche

Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 8.3 billion on a fully diluted basis.

Insulin offers new hope for the treatment of acute pancreatitis

FRIDAY, 22 AUGUST 2014

Acute pancreatitis involves the pancreas digesting itself resulting in severe abdominal pain, vomiting and systemic inflammation. Every year in the UK around 20,000 patients are diagnosed with the disease resulting in 1000 deaths. There is no immediate cure and treatment is restricted to intravenous fluid and nutritional support.

Breaking World Pharma News

Friday, 29 August 2014